Table 2. Risk of severe COVID outcomes among people on MOUD in Arizona during COVID by selected covariates, 2021 (N = 131).
| Total# (% total sample), N = 131 | High Risk for COVID Severe Outcomes per CDC (n = 53) | |
|---|---|---|
| #(% subsample) | ||
| Methadone only patient | 96 (73.3%) | 42 (43.8%) |
| Buprenorphine only patient | 33 (25.2%) | 9 (27.3%) |
| Both Methadone and Buprenorphine | 2 (1.5%) | 2 (100%) |
| Urban | 94 (71.8%) | 40 (42.6%) |
| Rural | 22 (16.7%) | 9 (40.9%) |
| Urban/Rural mix | 15 (11.5%) | 4 (26.7%) |
| Unhoused at some point during COVID | 20 (15.3%) | 9 (45.0%) |
| Time on Buprenorphine (Months) | Mean = 35.5 | Mean = 33.0 months |
| Time on Methadone (Months) | Mean = 38.6 | Mean = 49.2 months* |
| Age (years) | Mean age = 40 | Mean = 40.4 yrs* |
| BIPOC | 42 (32.1%) | 15(35.7%) |
| Had to go to the clinic daily to get medication (all MOUD) | 68 (51.9%) | 26 (38.2%) |
| Had to go to the clinic daily (Methadone only) | 52 (39.7%) | 20 (47.6%) |
*Independent samples t-test yielded mean differences at the p ≤ .05 level.